CA2380009A1 - Methodes d'inhibition de l'osteoclastogenese - Google Patents

Methodes d'inhibition de l'osteoclastogenese Download PDF

Info

Publication number
CA2380009A1
CA2380009A1 CA002380009A CA2380009A CA2380009A1 CA 2380009 A1 CA2380009 A1 CA 2380009A1 CA 002380009 A CA002380009 A CA 002380009A CA 2380009 A CA2380009 A CA 2380009A CA 2380009 A1 CA2380009 A1 CA 2380009A1
Authority
CA
Canada
Prior art keywords
amino acid
linkage
absent
amide
covalent linkage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002380009A
Other languages
English (en)
Inventor
Mark I. Greene
Ramachandran Murali
Kazuhiro Aoki
William Carle Horne
Roland Baron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
University of Pennsylvania Penn
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2380009A1 publication Critical patent/CA2380009A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des méthodes destinées à inhiber l'ostéoclastogenèse et l'activité des ostéoclastes. L'invention concerne également des méthodes de traitement de patients atteints de maladies caractérisées par une perte osseuse. La présente invention concerne en outre des peptides et des analogues de peptides mis au point à partir d'une boucle de fixation d'un élément de la superfamille de récepteurs de facteur de nécrose tumorale (TNF-R). Selon ces méthodes, on administre au patient une quantité d'inhibiteur efficace pour inhiber l'ostéoclastogenèse. L'invention concerne également des méthodes de modulation de la maturation des cellules dendritiques, de la prolifération des lymphocytes T, et/ou des systèmes récepteurs CD40 chez un individu. Ces méthodes consistent à administrer à l'individu une quantité d'inhibiteur efficace pour moduler la maturation des cellules dendritiques, la prolifération des lymphocytes T, et/ou les systèmes récepteurs CD40.
CA002380009A 1999-07-28 2000-07-28 Methodes d'inhibition de l'osteoclastogenese Abandoned CA2380009A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14609099P 1999-07-28 1999-07-28
US60/146,090 1999-07-28
PCT/US2000/020510 WO2001008699A1 (fr) 1999-07-28 2000-07-28 Methodes d'inhibition de l'osteoclastogenese

Publications (1)

Publication Number Publication Date
CA2380009A1 true CA2380009A1 (fr) 2001-02-08

Family

ID=22515815

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002380009A Abandoned CA2380009A1 (fr) 1999-07-28 2000-07-28 Methodes d'inhibition de l'osteoclastogenese

Country Status (5)

Country Link
EP (1) EP1221963A4 (fr)
JP (1) JP2003505514A (fr)
AU (1) AU777634B2 (fr)
CA (1) CA2380009A1 (fr)
WO (1) WO2001008699A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
JP4790179B2 (ja) * 1999-07-28 2011-10-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 破骨細胞活性を阻害する方法
CA2423052C (fr) 2000-09-22 2011-07-12 Immunex Corporation Methode de criblage d'agonistes ou d'antagonistes de l'activateur du recepteur de nf-kb
IL159478A0 (en) * 2001-06-22 2004-06-01 Daiichi Suntory Pharma Co Ltd Remedies for eosinophilic diseases
JP2014101274A (ja) * 2011-03-09 2014-06-05 Jitsubo Co Ltd 新規な架橋構造を含むｔｎｆレセプターループペプチドの模倣ペプチドを用いた医薬組成物
DK2684888T3 (da) * 2011-03-09 2019-08-19 Jitsubo Co Ltd Nye tværbundne peptider indeholdende ikke-peptid-tværbundet struktur, fremgangsmåde til syntetisering af tværbundne peptider og ny organisk forbindelse anvendt i fremgangsmåden
WO2016075221A1 (fr) * 2014-11-14 2016-05-19 Probiocon Gmbh Agent spécifique de rankl pour le traitement d'une maladie métastatique

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5955425A (en) * 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
AU693478B2 (en) * 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
RU2203286C2 (ru) * 1996-08-02 2003-04-27 Нэшнл Рисерч Каунсил ов Кэнэда Аналоги паратиреоидного гормона для лечения остеопороза
AU5901598A (en) * 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
GB9703109D0 (en) * 1997-02-14 1997-04-02 Smith & Nephew Compositions
US6265535B1 (en) * 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
WO1999012567A1 (fr) * 1997-09-10 1999-03-18 Uab Research Foundation Regulation de la formation d'osteoclastes par inhibition du facteur de cellules souches osteoblastiques
JP4790179B2 (ja) * 1999-07-28 2011-10-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 破骨細胞活性を阻害する方法

Also Published As

Publication number Publication date
EP1221963A1 (fr) 2002-07-17
AU6611100A (en) 2001-02-19
AU777634B2 (en) 2004-10-28
JP2003505514A (ja) 2003-02-12
EP1221963A4 (fr) 2006-03-22
WO2001008699A1 (fr) 2001-02-08

Similar Documents

Publication Publication Date Title
CA2291963C (fr) Analogues de peptides derives de recepteurs de facteur de necrose des tumeurs
US8003628B2 (en) Methods of inhibiting osteoclast activity
AU2005200650B2 (en) Methods of inhibiting osteoclast activity
AU2005200633A1 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
EP0975771B1 (fr) Proteines de fusion contenant le recepteur type ii du tgf-beta et proteines de fusion en tant que region constante d'une immunoglobuline
EP1087998A1 (fr) Proteines de fusion d'un variant du recepteur du type ii du tgf-beta et leurs methodes d'utilisation
US7329650B2 (en) Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
AU777634B2 (en) Methods of inhibiting osteoclastogenesis
JP2005534641A (ja) Ｆａｓペプチド模倣体およびその使用
US6682739B1 (en) Methods of inhibiting osteoclastogenesis
AU2008200757A1 (en) Methods of inhibiting osteoclast activity

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20130306